Home/Pipeline/Glioblastoma

Glioblastoma

ClinicalActive

Key Facts

Indication

Glioblastoma

Phase

Clinical

Status

Active

Company

Menarini

About Menarini

Menarini is a major, privately-held European pharmaceutical company with a diversified portfolio spanning pharmaceuticals, consumer healthcare, diagnostics, and derma-aesthetic medicine. It leverages a fully integrated model from R&D to global commercial execution, with a significant strategic focus on oncology and a strong partnering heritage. The company is actively investing in advanced science to build a pipeline for serious conditions while maintaining a core commitment to its values and corporate responsibility.

View full company profile

Therapeutic Areas

Oncology Anti Infectives Cardiometabolic Respiratory & Allergology Gastrointestinal Disorders Pain Men's Health Dermatology Aesthetic Medicine

Other Glioblastoma Drugs

Drug	Company	Phase	Status
Ropidoxuridine (IPdR)	Shuttle Pharmaceuticals	Phase 2	Active
LNTH-2505	Lantheus Medical Imaging	Preclinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
Glioblastoma Moonshot	Owkin	Research	Open Project
OPC-001 (PDC Candidate)	Oncopeptides	Phase 1/Window-of-Opportunity	Active (Fast-Track Designation)
αvβ3-targeted ADC	Xintela	Preclinical	Lead Optimization
Undisclosed	Biossil	Phase 2/3	Active
GLIX1	Hemispherian	Phase 1	Active
InC01	InCephalo Therapeutics	Pre-clinical	Active
Glioblastoma Combination Therapy	JLP Health	Pre-clinical	Active
ENV105	Kairos Pharma	IND Cleared	Active
LMP744	Gibson Oncology	Phase 2	Active